Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 22.214.171.124) - Pipeline Review, H2 2018
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 126.96.36.199) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The latest report Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2018, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 188.8.131.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 184.108.40.206) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 8 and 3 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.
Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Central Nervous System, Dermatology, Musculoskeletal Disorders and Undisclosed which include indications Psoriasis, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Autoimmune Disorders, Inflammation, Plaque Psoriasis (Psoriasis Vulgaris), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alopecia, Multiple Sclerosis, Rheumatoid Arthritis, Arthritis, Atopic Dermatitis (Atopic Eczema), B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hypersensitivity, Lupus Erythematosus, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Systemic Lupus Erythematosus, T-Cell Leukemia, Unspecified, Vitiligo and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Furthermore, this report also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 220.127.116.11) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.